Drugs / Putolizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07105852 | Jul 2025 → Jul 2027 expected | cholangiocarcinoma | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Putolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07105852 ↗ |
| Route | Intravenous | “Dosage: 200 mg, intravenous (IV) infusion” NCT07105852 ↗ |